The first clinical trials for a new vaccine targeting pneumococcal disease in people in Malawi have been launched. 

The human challenge trial will enrol 400 people in Malawi making it the biggest trial the country has seen to date.  

The launch of the trial comes as part of a collaboration between the Infection Innovation Consortium: iiCON and ImmunoBiology. The consortium is being led by the Liverpool School of Tropical Medicine and the trial is being funded by the Medical Research Council (MRC) with £3.2 ($4.3) million going towards it. 

Pneumococcal disease  

Invasive pneumococcal disease, which can vary from mild ear infection to severe sepsis, meningitis and pneumonia, is a global concern, with most child deaths occurring in low- and middle-income countries (LMICs). This has remained the case despite the development of successful vaccines that are effective against the strains of the disease that cause invasive pneumococcal disease in many developed countries. 

There are almost 100 different strains or serotypes of Streptococcus pneumoniae, the bacteria responsible for the disease. Current vaccines have to be engineered for each serotype since they target the sugars on the outer coatings of serotypes.  

PnuBioVax 

The vaccine being advanced between iiCON and ImmunoBiology, PnuBioVax, targets proteins which are common across all pneumococcus serotypes, including Serotype 3 pneumococcus (SPN3) a strain responsible for a rise in prevalence of invasive disease, potentially leading to a more holistic control response across many different strains of the disease.    

UK SME ImmBio developed PnuBioVax and successfully conducted Phase I safety and immunogenicity studies. iiCON has since collaborated with ImmBio to lead on the next phase of development of the vaccine, to bring it to Phase II clinical trials. 

If brought to market, the vaccine would target people at high risk of disease and those at high risk of transmitting infection to others. This would include immunosuppressed children and adults, particularly those with HIV. These communities are also exposed to high levels of antibiotics and so prevention of the spread of the SPN3 strain in these people will reduce the emergence of antimicrobial resistance.  

Professor Stephen Gordon, Director of Experimental Medicine at iiCON, said: “We’re very pleased to have reached this key milestone in the development of PnuBioVax, which will help to address an urgent health priority and public health issue both in Malawi and worldwide. Not only will it save lives, it will help to upskill and boost the local economy as we very much hope that the vaccine will eventually be manufactured and distributed locally. This way, we can ensure the communities that really need this vaccine will be receiving it. In the development of the vaccine we hope to cover multiple serotypes at low cost and effectively block community transmission.”  

 Graham Clarke, ImmBio Chairman, said: “The novel platform technology that ImmBio has developed generates a self-adjuvanting multi-component vaccine, needed to elicit a broad response. This Phase II trial is designed to generate data supporting prior evidence that response is strain-independent, able to protect against both current and new variants, cost-effectively. Positive data will support progression of other bacterial vaccines currently at pre-clinical stages, where strain variation is also a key challenge.”